Management of Patients with Neuroendocrine Tumors: Case Presentations Including Long-term, Open-label Pasireotide

#678

Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.

Aim(s): To present three cases with progressive NET on octreotide long-acting repeatable (octreotide LAR) and long-term stable disease while receiving pasireotide LAR.

Materials and methods: Pt A; aged 42 y, Asian man, low-grade small bowel NET diagnosed in 6/2001. Administered interferon starting 2/2003 for 49 mo; octreotide LAR (30 mg IM q28d) starting 1/2002 for 16 mo, increased to 60 mg IM q28d 5/2003 for 47 mo. Pt B; aged 75 y, Caucasian woman, low-grade small intestinal NET diagnosed in 1/2006. Administered octreotide LAR (100 µg IM) starting 5/2006 for 11 mo. Pt C; aged 50 y, Caucasian woman, low-grade small intestinal NET diagnosed in 8/2006. Received octreotide LAR (60 mg IM q28d) starting 11/2006 for five mo.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Wolin E

Authors: Wolin E, Giannone V, Hermasillo Resendiz K,

Keywords: somatostatin analog, pasireotide, carcinoid syndrome,